Canada markets open in 5 hours 15 minutes

Bionomics Limited (BNOX)

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Add to watchlist
0.8100-0.0363 (-4.29%)
At close: 04:00PM EDT
0.7835 -0.03 (-3.27%)
After hours: 07:46PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.8463
Open0.8500
Bid0.7705 x 100
Ask0.8453 x 100
Day's Range0.8000 - 0.8800
52 Week Range0.6500 - 6.4100
Volume647,999
Avg. Volume554,275
Market Cap10.73M
Beta (5Y Monthly)-0.11
PE Ratio (TTM)N/A
EPS (TTM)-2.0400
Earnings DateJul 23, 2024 - Jul 28, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.00
  • GlobeNewswire

    Bionomics Initiates AFFIRM-1, a Phase 3 Clinical Trial with BNC210 for Social Anxiety Disorder

    Topline results are expected in Q3 2025 ADELAIDE, Australia and CAMBRIDGE, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a biotechnology company developing novel, potential first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced the initiation of patient screening for the Phase 3 AFFIRM-1 trial evaluating the safety and effica

  • GlobeNewswire

    Bionomics Limited Announces Private Placement of up to $70.0 Million

    ADELAIDE, Australia and CAMBRIDGE, Mass., May 31, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (“Bionomics” or the “Company”), a clinical-stage biotechnology company developing novel, potential first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (“CNS”) disorders with high unmet medical need, today announced it has entered into a securities purchase agreement with an institutional accredited investor to purchase American

  • GlobeNewswire

    Bionomics to Present at the 2024 American Society of Clinical Psychopharmacology Annual Meeting

    ADELAIDE, Australia and CAMBRIDGE, Mass., May 20, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that Spyridon “Spyros” Papapetropoulos, M.D., PhD, President and Chief Executive Officer of Bionomics will be giving an oral presentati